Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (MLYS) priced its initial public offering on Feb 10, 2023 at $16.00 per share, within its $14.00–$16.00 range, raising $192M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $624.9M. BofA Securities was lead-left underwriter, joined by Evercore ISI, Stifel and Guggenheim and others. Latham & Watkins advised the company and A&O Shearman advised the underwriters.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for diseases driven by elevated aldosterone. Its candidate lorundrostat is an oral aldosterone synthase inhibitor being developed first for uncontrolled and resistant hypertension.

Status

IPO

Ticker

MLYS

Exchange

Nasdaq Global Select

Priced

Feb 10, 2023

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$192M

Market cap at IPO price

$624.9M

First filed

Jan 18, 2023

Underwriters

BofA Securities, Evercore ISI, Stifel, Guggenheim, Credit Suisse and Wells Fargo

Company counsel

Latham & Watkins

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.